Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer

BACKGROUND: Abiraterone is a standard treatment for men with castration-resistant prostate cancer (CRPC). We evaluated the antitumour activity of abiraterone following the synthetic oestrogen diethylstilboestrol (DES). METHODS: Castration-resistant prostate cancer patients treated with abiraterone w...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Omlin, A, J Pezaro, C, Zaidi, S, Lorente, D, Mukherji, D, Bianchini, D, Ferraldeschi, R, Sandhu, S, Dearnaley, D, Parker, C, Van As, N, de Bono, J S, Attard, G
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2013
Gaiak:
Short Communication
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3778298/
https://ncbi.nlm.nih.gov/pubmed/23928659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.446
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak